Immobilization of an active agent on a substrate

Patent metadata

Field	Value
Publication number	US-9642949-B2
Application number	US-201414212325-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

First claim

What is claimed is:

1. A substrate having an active agent immobilized on a surface thereof, the substrate comprising a layer of a primer compound on the substrate surface, wherein the layer of the primer compound includes a compound including a trihydroxyphenyl group coupled thereto selected from the group consisting of gallic acid, phloroglucinol carboxylic acid, gallamide, 5-methyl-benzene-1,2,3-triol, 3,4,5-trihydroxybenzaldehyde, 2,3,4-trihydroxybenzaldehyde, gallacetophenone, 3,4,5-trihydroxybenzamide, 2,3,4-trihydroxybenzoic acid, 5-hydroxydopamine hydrochloride, methyl gallate, derivatives thereof, salts of the foregoing, and combinations thereof, and wherein the compound comprising the trihydroxyphenyl group includes an active agent coupled thereto.

2. The substrate of claim 1 , wherein the substrate is metal, inorganic oxide, ceramic, semiconductor, or polymeric.

3. The substrate of claim 1 , wherein the trihydroxyphenyl group is selected from the group consisting of a small molecule comprising a trihydroxyphenyl group and a polymer comprising a trihydroxyphenyl group.

4. The substrate of claim 1 , further comprising a linker compound coupled to the trihydroxyphenyl group and/or the primer compound, wherein the linker compound includes an active agent coupled thereto.

5. The substrate of claim 1 , wherein the primer layer on the article has a thickness in a range of about 0.1 nm to about 100 μm.

6. The substrate of claim 1 , wherein the primer is selected from the group consisting of oligosaccharides, polyamines, amino functionalized silanes, and combinations thereof.

7. The substrate of claim 1 , wherein the active agent is selected from the group consisting of antimicrobial agents, antifouling agents, anticoagulants, anti-inflammatory agents, antithrombogenic agents, and combinations of the foregoing.

8. The substrate of claim 1 , wherein the active agent is selected from the group consisting of chitosan, linear polyethylene glycol, looped polyethylene glycol, polyethylene glycol derivatives, fractionated heparin, unfractionated heparin, heparin derivatives, quaternary ammonium polymers, albumin, polyethylenimine, 4-hydroxycoumarin derivatives, and combinations of the foregoing.

9. A medical device comprising the substrate of claim 1 .

10. The medical device of claim 9 , wherein the medical device comprises an extracorporeal blood circuit.

11. The medical device of claim 9 , wherein the medical device comprises tubing, the substrate comprises polysulfone, the primer compound comprises an oligosaccharide, and the active agent comprises heparin.

Assignees

• Baxter Int
• Baxter Healthcare Sa
• Univ Northwestern

Inventors

• Hai Ton That
• Green John-Bruce Devault
• Fulghum Timothy Michael
• Messersmith Phillip Byron
• Sileika Tadas Stanislovas

Classifications

• A61L31/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L33/08 Primary

  Polysaccharides · CPC title

• A61L31/048

  obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence) · CPC title

• A61L29/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)} · CPC title

• A61L33/0011

  Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate · CPC title